BioNTech (NASDAQ:BNTX) Raised to “Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of BioNTech (NASDAQ:BNTX) from a hold rating to a buy rating in a research report report published on Tuesday morning, MarketBeat reports. They currently have $150.00 price objective on the stock, up from their previous price objective of $96.00.

Other equities analysts have also issued reports about the stock. Hsbc Global Res upgraded shares of BioNTech from a hold rating to a strong-buy rating in a report on Friday, August 2nd. TD Cowen lowered their price objective on BioNTech from $98.00 to $85.00 and set a hold rating for the company in a research report on Tuesday, August 6th. HC Wainwright restated a buy rating and issued a $113.00 target price on shares of BioNTech in a research report on Monday. JPMorgan Chase & Co. upgraded BioNTech from an underweight rating to a neutral rating and increased their price target for the stock from $91.00 to $125.00 in a report on Monday. Finally, HSBC upgraded shares of BioNTech from a hold rating to a buy rating in a report on Friday, August 2nd. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $124.54.

BioNTech Trading Down 2.7 %

BNTX stock opened at $112.51 on Tuesday. The business’s 50-day moving average is $89.71 and its 200 day moving average is $90.31. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The stock has a market cap of $26.75 billion, a price-to-earnings ratio of 225.02 and a beta of 0.23. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.86) earnings per share. On average, sell-side analysts anticipate that BioNTech will post -2.8 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Primecap Management Co. CA raised its holdings in BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after acquiring an additional 131,490 shares in the last quarter. Harding Loevner LP purchased a new stake in shares of BioNTech in the 4th quarter valued at approximately $410,984,000. Capital World Investors raised its holdings in shares of BioNTech by 0.5% in the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock valued at $87,002,000 after purchasing an additional 4,369 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after purchasing an additional 24,426 shares during the last quarter. Finally, Candriam S.C.A. boosted its position in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.